EyePoint Inc. stocks have been trading down by -69.69 percent amid heightened concern over its latest clinical trial setback.
Click Here for a Millionaire's POV on Trading EYPT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- An amended Form 144/A filing indicates a proposed sale of EyePoint Pharmaceuticals securities by an insider or major holder.
- The filing signals an intention to dispose of EYPT securities, not accumulate more, which often pressures sentiment.
- Such Form 144/A filings in EYPT are closely watched by traders as potential clues to insider confidence and near‑term risk.
Live Update At 09:17:15 EDT: On Monday, August 17, 2026 EyePoint Inc. stock [NASDAQ: EYPT] is trending down by -69.69%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
EyePoint Pharmaceuticals, trading under ticker EYPT, is a classic high‑risk biotech story on the numbers. Revenue over the last year sits around $31.4M, but the company is burning far more than it brings in. EYPT posted about $94.5M in net losses for the latest reported quarter ending 2026/06/30, driven largely by heavy research and development spending of roughly $83.6M. That tells traders EYPT is still in “build the science, worry about profits later” mode.
Margins underline the point. Profitability ratios are deep in the red, with negative returns on equity and assets, and price‑to‑sales near 456, which is extremely rich for a company without positive earnings. On the flip side, EYPT’s balance sheet is not falling apart. Cash and equivalents plus short‑term investments total about $180.5M, current assets are roughly $188.8M against current liabilities of $41.9M, giving EyePoint Pharmaceuticals a strong current ratio above 4. That means, for now, EYPT has room to keep funding operations.
More Breaking News
- MYSZ Stock Rockets On Volatility As Traders Circle
- HL Stock Climbs As Hecla Mining Flexes Cash And Cost Strength
- DFSC Stock Jumps As Traders Pile Into High-Volatility Move
- LBGJ Stock Holds Gains As Traders Focus On Low Valuation
On the chart side, EYPT has climbed from the low‑$12s to the mid‑$14s over the recent multi‑day stretch, signaling a short‑term uptrend that traders are tracking closely.
Why Traders Are Watching EYPT Insider Activity
What really has traders circling EYPT right now is the amended Form 144/A filing. This filing shows an insider or major holder of EyePoint Pharmaceuticals planning to sell securities, not buy more. Anytime a big holder looks to unload, active traders pay attention. It often acts like a yellow light at an intersection — you do not slam the brakes automatically, but you stop flooring it.
For EYPT, the timing is key. The daily chart shows a strong push from roughly $12.19 on 2026/07/24 up to $14.75 on 2026/08/14. That’s a solid multi‑week grind higher, with EYPT closing green on several sessions and even spiking to $14.76 intraday. When a stock like EyePoint Pharmaceuticals runs and then insider or major‑holder selling shows up in filings, momentum traders start asking who’s on the other side of their trade.
Intraday price action also supports the idea of shifting sentiment. The 5‑minute data show EYPT trading around $15.27 in the very early pre‑market, then cracking hard into the $4–$6 area, with sharp swings between $3.50 and $6.90 before stabilizing around the mid‑$4s to low‑$5s in the later pre‑market window. That’s a massive gap‑down pattern for EYPT, paired with wild volatility — exactly the kind of action that tells short‑term traders that supply is suddenly overwhelming demand.
The Form 144/A itself does not say anything about EyePoint Pharmaceuticals’ drug pipeline or long‑term science. But for EYPT day traders and swing traders, it raises questions about whether near‑term upside is capped while a large seller works through shares.
Conclusion
EYPT now sits at an interesting crossroads. On one hand, EyePoint Pharmaceuticals shows a classic biotech financial profile: high R&D, steep losses, but a cash pile that buys time. EYPT’s strong liquidity ratios suggest the company is not in immediate financial danger, and the recent multi‑week climb from the low‑$12s into the mid‑$14s shows there was real bullish momentum on the tape.
On the other hand, the amended Form 144/A filing signals that an insider or major holder is preparing to sell EYPT securities. For many traders, that is not something to ignore. It can weigh on sentiment, create overhead supply, and turn strong bounces in EYPT into opportunities for the seller to distribute more shares. The violent pre‑market drop from around $15 to the $4–$6 range reinforces that risk‑off tone around EyePoint Pharmaceuticals in the short term.
For active traders studying EYPT, this is a textbook spot to follow the rules that Tim Sykes and his community hammer home: “The market doesn’t care about your opinion, only price action and risk management.” In the same spirit of disciplined trading, it aligns closely with the mindset emphasized by other trading educators; as Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. That means watching how EyePoint Pharmaceuticals trades around key support and resistance, respecting the volatility, and being ready to cut losses fast if the insider selling pressure keeps leaning on the stock. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.